BetterLife Pharma Appoints New Director
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha brings 25 years of experience in investment banking, business development, and asset management, along with expertise in public company governance and compliance. He holds a Doctorate of Dental Surgery from the University of Western Ontario and a Bachelor of Pharmaceutical Science from UBC.
As the largest shareholder of BetterLife, Dr. Sangha expressed confidence in BETR-001, describing it as the best asset in its class for treating depression, anxiety, PTSD, and addiction. The company is focusing on developing non-hallucinogenic compounds for psychiatric and neurological disorders, with plans to advance BETR-001 to human clinical trials in the near future.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha nominato Dr. Steven Sangha nel suo Consiglio di Amministrazione. Il Dr. Sangha porta con sé 25 anni di esperienza in investment banking, sviluppo commerciale e gestione patrimoniale, oltre a una competenza nella governance e conformità delle aziende pubbliche. Ha conseguito un Dottorato in Chirurgia Dentale presso l'Università di Western Ontario e una Laurea in Scienze Farmaceutiche presso l'UBC.
In qualità di maggiore azionista di BetterLife, il Dr. Sangha ha espresso fiducia in BETR-001, descrivendolo come il miglior asset della sua categoria per il trattamento della depressione, dell'ansia, del PTSD e della dipendenza. L'azienda si sta concentrando sullo sviluppo di composti non allucinogeni per disturbi psichiatrici e neurologici, con piani per avanzare BETR-001 a sperimentazioni cliniche umane nel prossimo futuro.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) ha nombrado al Dr. Steven Sangha en su Junta Directiva. El Dr. Sangha aporta 25 años de experiencia en banca de inversión, desarrollo empresarial y gestión de activos, junto con experiencia en gobernanza y cumplimiento de empresas públicas. Posee un Doctorado en Cirugía Dental de la Universidad de Western Ontario y una Licenciatura en Ciencias Farmacéuticas de la UBC.
Como el mayor accionista de BetterLife, el Dr. Sangha expresó confianza en BETR-001, describiéndolo como el mejor activo en su clase para tratar la depresión, la ansiedad, el PTSD y la adicción. La empresa se está centrando en el desarrollo de compuestos no alucinógenos para trastornos psiquiátricos y neurológicos, con planes para avanzar BETR-001 a ensayos clínicos humanos en un futuro cercano.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF)는 Dr. Steven Sangha를 이사회에 임명했습니다. Dr. Sangha는 투자은행, 사업 개발 및 자산 관리 분야에서 25년의 경험을 가지고 있으며, 공공 기업의 거버넌스 및 규정 준수에 대한 전문성을 갖추고 있습니다. 그는 웨스턴 온타리오 대학교에서 치과 수술 박사 학위를, UBC에서 약학 학사 학위를 취득했습니다.
BetterLife의 최대 주주인 Dr. Sangha는 BETR-001에 대한 신뢰를 표명하며, 이를 우울증, 불안, PTSD 및 중독 치료를 위한 최고의 자산으로 설명했습니다. 이 회사는 정신과 및 신경 장애를 위한 비환각 화합물 개발에 집중하고 있으며, 가까운 미래에 BETR-001을 인간 임상 시험으로 진행할 계획입니다.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) a nommé Dr. Steven Sangha au sein de son Conseil d'Administration. Le Dr. Sangha apporte 25 ans d'expérience en banque d'investissement, développement commercial et gestion d'actifs, ainsi qu'une expertise en gouvernance et conformité des entreprises publiques. Il détient un Doctorat en Chirurgie Dentaire de l'Université de Western Ontario et un Bachelor en Sciences Pharmaceutiques de l'UBC.
En tant que principal actionnaire de BetterLife, le Dr. Sangha a exprimé sa confiance dans BETR-001, le décrivant comme le meilleur actif de sa catégorie pour traiter la dépression, l'anxiété, le PTSD et la dépendance. L'entreprise se concentre sur le développement de composés non hallucinogènes pour les troubles psychiatriques et neurologiques, avec des projets d'avancer BETR-001 vers des essais cliniques humains dans un avenir proche.
BetterLife Pharma (CSE: BETR / OTCQB: BETRF) hat Dr. Steven Sangha in seinen Vorstand berufen. Dr. Sangha bringt 25 Jahre Erfahrung in der Investmentbanking, Geschäftsentwicklung und Vermögensverwaltung mit, sowie Expertise in der Governance und Compliance von börsennotierten Unternehmen. Er hat einen Doktortitel in Zahnmedizin von der University of Western Ontario und einen Bachelor in Pharmazeutischen Wissenschaften von der UBC.
Als größter Aktionär von BetterLife äußerte Dr. Sangha Vertrauen in BETR-001 und bezeichnete es als das beste Asset seiner Klasse zur Behandlung von Depressionen, Angstzuständen, PTSD und Sucht. Das Unternehmen konzentriert sich auf die Entwicklung nicht-halluzinogener Verbindungen für psychiatrische und neurologische Störungen und plant, BETR-001 in naher Zukunft in klinischen Studien am Menschen voranzutreiben.
- Appointment of largest shareholder to Board indicates strong insider confidence
- New director brings 25 years of investment banking and business development experience
- BETR-001 advancing towards human clinical trials phase
- Added expertise in public company governance and compliance
- BETR-001 still in pre-clinical phase, pending human trials
- Significant development and regulatory hurdles remain before commercialization
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office.
Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. Dr. Sangha commented, “I am honored and excited to join BetterLife as a board member. I have been a long time supporter and have now become the largest shareholder of BetterLife over the past few years. I believe BETR-001 is the best asset in its class and will be disruptive to help those suffering from depression, anxiety, PTSD and addiction. I am looking forward to getting BETR-001 to the finish line so it can proceed with human clinical trials in the very near future.”
“We are extremely pleased to welcome Dr. Sangha to our Board of Directors. He brings a wealth of experience in the biotech space, which will be very valuable as we execute our plans to develop non-hallucinogenic compounds to treat psychiatric and neurological disorders. We look forward to working with Dr. Sangha and his associates in the investment community”, commented Ahmad Doroudian, CEO of BetterLife.
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
Contact
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
Who is the newest board member appointed to BetterLife Pharma (BETRF)?
What is BetterLife Pharma's (BETRF) main product in development?
What are Dr. Sangha's qualifications for joining BetterLife's (BETRF) board?
What is the next development milestone for BetterLife's (BETRF) BETR-001?
